Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Hormone Receptor-Positive Breast Carcinoma|Locally Advanced Cutaneous Melanoma|Metastatic Acral Lentiginous Melanoma|Metastatic Conjunctival Melanoma|Metastatic Cutaneous Melanoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Mucosal Melanoma|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Acral Lentiginous Melanoma|Recurrent Cutaneous Melanoma|Recurrent Mucosal Melanoma|Refractory HER2-Negative Breast Carcinoma|Unresectable Acral Lentiginous Melanoma|Unresectable Cutaneous Melanoma|Unresectable Mucosal Melanoma
Interventions: BIOLOGICAL: Neoantigen Peptide Vaccine|BIOLOGICAL: Nivolumab|DRUG: Poly ICLC
Sponsor: Fred Hutchinson Cancer Center
Collaborators: Amazon.com Services LLC